Palisade Bio Inc.(PALI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

PALI Palisade Bio Inc.

Closed 12-18 16:00:00 EST

1.67

-0.01

-0.60%

盘后1.70

+0.03+1.80%

19:00 EST

High1.77	Low1.65	Vol1.88M
Open1.73	D1 Closing1.68	Amplitude6.90%
Mkt Cap248.83M	Tradable Cap175.35M	Total Shares149.00M
T/O3.20M	T/O Rate1.79%	Tradable Shares105.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"PALI","market":"US","secType":"STK","nameCN":"Palisade Bio Inc.","latestPrice":1.67,"timestamp":1766091600000,"preClose":1.68,"halted":0,"volume":1875488,"hourTrading":{"tag":"盘后","latestPrice":1.7,"preClose":1.67,"latestTime":"19:00 EST","volume":7288,"amount":12172.0099,"timestamp":1766102404421},"delay":0,"floatShares":105000000,"shares":149000000,"eps":-3.573685,"marketStatus":"Closed","change":-0.01,"latestTime":"12-18 16:00:00 EST","open":1.73,"high":1.77,"low":1.654,"amount":3200386.3621568,"amplitude":0.069048,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.573685,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1766134800000},"marketStatusCode":5,"adr":0,"listingDate":1188187200000,"exchange":"NASDAQ","adjPreClose":1.68,"preHourTrading":{"tag":"盘前","latestPrice":1.7232,"preClose":1.68,"latestTime":"09:27 EST","volume":39283,"amount":67184.2300026,"timestamp":1766068059961},"postHourTrading":{"tag":"盘后","latestPrice":1.7,"preClose":1.67,"latestTime":"19:00 EST","volume":7288,"amount":12172.0099,"timestamp":1766102404421},"volumeRatio":0.35714},"requestUrl":"/m/hq/s/PALI/tweets","defaultTab":"tweets","newsList":[{"id":"2588591056","title":"BRIEF-Palisade Bio Strengthens Clinical Leadership Team With Appointment Of James Izanec","url":"https://stock-news.laohu8.com/highlight/detail?id=2588591056","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588591056?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:46","pubTimestamp":1764683201,"startTime":"0","endTime":"0","summary":"BRIEF-Palisade Bio Strengthens Clinical Leadership Team With Appointment Of James IzanecDec 2 (Reuters) - Palisade Bio Inc PALI.O:PALISADE BIO STRENGTHENS CLINICAL LEADERSHIP TEAM WITH APPOINTMENT OF ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUACCYRBH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PALI","BK4007","BK4139"],"gpt_icon":0},{"id":"2588056593","title":"Palisade Bio Strengthens Clinical Leadership Team With Appointment of James Izanec, Md, Agaf as Vice President, Clinical Development","url":"https://stock-news.laohu8.com/highlight/detail?id=2588056593","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588056593?lang=en_us&edition=fundamental","pubTime":"2025-12-02 21:45","pubTimestamp":1764683100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nTUACCYRBH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PALI","BK4139","BK4007"],"gpt_icon":0},{"id":"2582998103","title":"Palisade Bio price target raised to $8 from $2 at Maxim","url":"https://stock-news.laohu8.com/highlight/detail?id=2582998103","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582998103?lang=en_us&edition=fundamental","pubTime":"2025-11-12 01:45","pubTimestamp":1762883132,"startTime":"0","endTime":"0","summary":"Maxim raised the firm’s price target on Palisade Bio (PALI) to $8 from $2 and keeps a Buy rating on the shares, citing lower risk as the firm conte...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palisade-bio-price-target-raised-to-8-from-2-at-maxim-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palisade-bio-price-target-raised-to-8-from-2-at-maxim-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","PALI","BK4007"],"gpt_icon":0},{"id":"2581881099","title":"Palisade Bio Inc  expected to post a loss of 27 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581881099","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581881099?lang=en_us&edition=fundamental","pubTime":"2025-11-07 23:02","pubTimestamp":1762527739,"startTime":"0","endTime":"0","summary":"Palisade Bio Inc  expected to post a loss of27cents a share - Earnings Preview Palisade Bio Inc PALI.OQ PALI.O is expected to  show no change in quarterly revenue when it reports  results on November ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ22T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PALI","BK4007"],"gpt_icon":0},{"id":"2579011901","title":"Palisade Bio Inc. Announces Date for Upcoming Special Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2579011901","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579011901?lang=en_us&edition=fundamental","pubTime":"2025-10-29 21:36","pubTimestamp":1761744993,"startTime":"0","endTime":"0","summary":"Palisade Bio Inc. has announced that it will hold a virtual Special Meeting of Stockholders on December 3, 2025. The meeting will be conducted online via live webcast.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palisade Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 28, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251029:nNDL9J5h7M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PALI","BK4007","BK4139"],"gpt_icon":0},{"id":"2578213954","title":"BRIEF-Palisade Bio Appoints Sharon Skare As Vice President, Global Head Of Clinical Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2578213954","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578213954?lang=en_us&edition=fundamental","pubTime":"2025-10-28 20:49","pubTimestamp":1761655761,"startTime":"0","endTime":"0","summary":"BRIEF-Palisade Bio Appoints Sharon Skare As Vice President, Global Head Of Clinical OperationsPalisade Bio Inc PALI.O:PALISADE BIO APPOINTS SHARON SKARE AS VICE PRESIDENT, GLOBAL HEAD OF CLINICAL OPERATIONSSource text: ID:nGNX1tfntPFurther company coverage: PALI.O","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251028:nTUA62TNVY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","PALI","BK4139"],"gpt_icon":0},{"id":"2577889455","title":"Palisade Bio Inc. held annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2577889455","media":"Reuters","labels":["shareholding","conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577889455?lang=en_us&edition=fundamental","pubTime":"2025-10-21 06:49","pubTimestamp":1761000574,"startTime":"0","endTime":"0","summary":"Palisade Bio Inc. held its annual meeting of stockholders on October 17, 2025. Stockholders elected three directors to the board. The selection of Baker Tilly US, LLP as independent registered public accounting firm for the fiscal year ending December 31, 2025 was ratified. An amendment to the Amended and Restated Certificate of Incorporation to allow for a reverse stock split at a ratio between 1-for-5 and 1-for-50, at the discretion of the board of directors, was approved.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palisade Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on Oc","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL5Sg05Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PALI","BK4007","BK4139"],"gpt_icon":0},{"id":"2576573318","title":"Palisade Bio Inc. Announces Date for Upcoming Special Stockholders Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2576573318","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576573318?lang=en_us&edition=fundamental","pubTime":"2025-10-20 21:22","pubTimestamp":1760966520,"startTime":"0","endTime":"0","summary":"Palisade Bio, Inc. has announced it will hold a Special Meeting of Stockholders on December 3, 2025. The meeting will be conducted virtually via live webcast.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Palisade Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on October 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nNDL6TX3mV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PALI","BK4139","BK4007"],"gpt_icon":0},{"id":"2576854178","title":"BRIEF-Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2576854178","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576854178?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:46","pubTimestamp":1760964414,"startTime":"0","endTime":"0","summary":"BRIEF-Palisade Bio Announces First Patients Dosed in Phase 1b Study of Oral First-In-Class PDE4 Inhibitor Prodrug, PALI-2108, for the Treatment of Fibrostenotic Crohn’s Disease (FSCD)Oct 20 (Reuters) ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nTUABXBGG0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PALI","BK4139","BK4007"],"gpt_icon":0},{"id":"2576854187","title":"Palisade Bio Inc - Data to Support Phase 2 Ind Submissions to FDA in H1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2576854187","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576854187?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:45","pubTimestamp":1760964300,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nTUABXBGG0:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PALI","BK4139"],"gpt_icon":0},{"id":"2576854167","title":"Palisade Bio Inc - Topline Data for Pali-2108 Study Expected in Q1 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2576854167","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576854167?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:45","pubTimestamp":1760964300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nTUABXBGG0:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PALI","BK4139","BK4007"],"gpt_icon":0},{"id":"2576188854","title":"Palisade Bio Announces First Patients Dosed in Phase 1B Study of Oral First-in-Class Pde4 Inhibitor Prodrug, Pali-2108, for the Treatment of Fibrostenotic Crohn’s Disease (Fscd)","url":"https://stock-news.laohu8.com/highlight/detail?id=2576188854","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2576188854?lang=en_us&edition=fundamental","pubTime":"2025-10-20 20:45","pubTimestamp":1760964300,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251020:nTUABXBGG0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PALI","BK4139"],"gpt_icon":0},{"id":"2575401862","title":"Palisade Bio granted Canadian patent covering PALI-2108 composition","url":"https://stock-news.laohu8.com/highlight/detail?id=2575401862","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575401862?lang=en_us&edition=fundamental","pubTime":"2025-10-13 20:50","pubTimestamp":1760359805,"startTime":"0","endTime":"0","summary":"Palisade Bio (PALI) announced that the Canadian Intellectual Property Office has granted patent number 3,174,137 titled, “Gut Microbiota Bioactivat...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/palisade-bio-granted-canadian-patent-covering-pali-2108-composition-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/palisade-bio-granted-canadian-patent-covering-pali-2108-composition-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","PALI"],"gpt_icon":0},{"id":"2575099124","title":"Palisade Bio Granted Canadian Patent Covering Composition of Lead Product Candidate PALI-2108","url":"https://stock-news.laohu8.com/highlight/detail?id=2575099124","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2575099124?lang=en_us&edition=fundamental","pubTime":"2025-10-13 20:45","pubTimestamp":1760359500,"startTime":"0","endTime":"0","summary":"PALI-2108 is the first and only PDE4 inhibitor designed to target terminal ileum and colon for fibrostenotic Crohn’s disease (FSCD) and ulcerative colitis (UC) to address significant unmet medical nee","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/13/3165548/0/en/Palisade-Bio-Granted-Canadian-Patent-Covering-Composition-of-Lead-Product-Candidate-PALI-2108.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PALI","BK4007","BK4139"],"gpt_icon":0},{"id":"2573777927","title":"Steven Cohen Doubles The S&P 500 — And His Next Bet's All Gut","url":"https://stock-news.laohu8.com/highlight/detail?id=2573777927","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2573777927?lang=en_us&edition=fundamental","pubTime":"2025-10-08 23:30","pubTimestamp":1759937400,"startTime":"0","endTime":"0","summary":"Steven Cohen's Point72 Asset Management has doubled the S&P 500's three-year return and is investing in this biotech firm...","market":"us","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/10/08/Wall-Street-ai6.png?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/10/08/Wall-Street-ai6.png?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/hedge-funds/25/10/48104197/steven-cohen-doubles-the-sp-500-and-his-next-bets-all-gut","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/markets/hedge-funds/25/10/48104197/steven-cohen-doubles-the-sp-500-and-his-next-bets-all-gut","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["VOO","ESmain","BK4581","IVV",".SPX","MESmain","BK4588","SH","PALI","BK4007","OEF","BK4550","SPXU","BK4585","BK4504","SPY","SDS","BK4139","BK4559","OEX","SSO","BK4534","UPRO"],"gpt_icon":0},{"id":"2572265535","title":"Palisade Bio Closes $138 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2572265535","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572265535?lang=en_us&edition=fundamental","pubTime":"2025-10-03 05:48","pubTimestamp":1759441686,"startTime":"0","endTime":"0","summary":"Palisade Bio (PALI) announced late Thursday that it had closed its $138 million public offering, in a push to fund the development of PALI-2108 to treat ulcerative colitis.The offering included 197.2 million shares at $0.70 per share.Shares of the company rose 8% in recent after-market activity.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["PALI","BK4139","BK4007"],"gpt_icon":0},{"id":"2572532431","title":"Palisade Bio Prices Upsized $120 Million Underwritten Public Offering; Shares Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2572532431","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572532431?lang=en_us&edition=fundamental","pubTime":"2025-10-01 21:58","pubTimestamp":1759327104,"startTime":"0","endTime":"0","summary":"Palisade Bio (PALI) said Wednesday it priced an upsized underwritten public offering of about 171.4 million shares priced at $0.70 per share to raise gross proceeds of $120 million.Underwriters were g","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4139","PALI"],"gpt_icon":0},{"id":"2572349495","title":"Palisade Bio Announces Pricing of Upsized $120 Million Underwritten Public Offering of Common Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=2572349495","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572349495?lang=en_us&edition=fundamental","pubTime":"2025-10-01 21:20","pubTimestamp":1759324800,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251001:nTUA9V9HWL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","PALI","BK4139"],"gpt_icon":0},{"id":"2570858889","title":"BRIEF-Palisade Bio Announces Adjournment Of Special Meeting Of Stockholders Due To Lack Of Quorum","url":"https://stock-news.laohu8.com/highlight/detail?id=2570858889","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570858889?lang=en_us&edition=fundamental","pubTime":"2025-09-27 05:43","pubTimestamp":1758923008,"startTime":"0","endTime":"0","summary":"BRIEF-Palisade Bio Announces Adjournment Of Special Meeting Of Stockholders Due To Lack Of QuorumSept 26 (Reuters) - Palisade Bio Inc PALI.O:PALISADE BIO ANNOUNCES ADJOURNMENT OF SPECIAL MEETING OF ST","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nFWN3VD13S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PALI","BK4007"],"gpt_icon":0},{"id":"2570832890","title":"Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum","url":"https://stock-news.laohu8.com/highlight/detail?id=2570832890","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2570832890?lang=en_us&edition=fundamental","pubTime":"2025-09-27 04:05","pubTimestamp":1758917131,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250926:nFWN3VD13S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["PALI","BK4139","BK4007"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.palisadebio.com","stockEarnings":[{"period":"1week","weight":-0.2},{"period":"1month","weight":-0.1884},{"period":"3month","weight":1.8094},{"period":"6month","weight":1.7215},{"period":"1year","weight":-0.1158},{"period":"ytd","weight":0.0182}],"compareEarnings":[{"period":"1week","weight":-0.0235},{"period":"1month","weight":0.0086},{"period":"3month","weight":0.0138},{"period":"6month","weight":0.1298},{"period":"1year","weight":0.1111},{"period":"ytd","weight":0.1456}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is LB1148, an oral liquid formulation of the digestive enzyme inhibitor tranexamic acid to reduce the formation of postoperative adhesions, postoperative ileus, and return of bowel function in adults. It has a license agreement with the Regents of the University of California; and co-development and distribution agreement with Newsoara Biopharma Co., Ltd. Palisade Bio, Inc. is based in Carlsbad, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.578947,"avgChangeRate":0.022497},{"month":2,"riseRate":0.421053,"avgChangeRate":-0.042764},{"month":3,"riseRate":0.473684,"avgChangeRate":0.009436},{"month":4,"riseRate":0.421053,"avgChangeRate":-0.042784},{"month":5,"riseRate":0.263158,"avgChangeRate":-0.085738},{"month":6,"riseRate":0.263158,"avgChangeRate":-0.050282},{"month":7,"riseRate":0.421053,"avgChangeRate":-0.087061},{"month":8,"riseRate":0.368421,"avgChangeRate":-0.088321},{"month":9,"riseRate":0.526316,"avgChangeRate":0.073462},{"month":10,"riseRate":0.210526,"avgChangeRate":-0.030579},{"month":11,"riseRate":0.421053,"avgChangeRate":-0.001568},{"month":12,"riseRate":0.421053,"avgChangeRate":0.002636}],"exchange":"NASDAQ","name":"Palisade Bio Inc.","nameEN":"Palisade Bio Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Palisade Bio Inc.(PALI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Palisade Bio Inc.(PALI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Palisade Bio Inc.,PALI,Palisade Bio Inc.股票,Palisade Bio Inc.股票老虎,Palisade Bio Inc.股票老虎国际,Palisade Bio Inc.行情,Palisade Bio Inc.股票行情,Palisade Bio Inc.股价,Palisade Bio Inc.股市,Palisade Bio Inc.股票价格,Palisade Bio Inc.股票交易,Palisade Bio Inc.股票购买,Palisade Bio Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Palisade Bio Inc.(PALI),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Palisade Bio Inc.(PALI) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction